Compare KELYB & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | DSGN |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.7M | 853.8M |
| IPO Year | 1994 | 2021 |
| Metric | KELYB | DSGN |
|---|---|---|
| Price | $22.67 | $10.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 8.6K | ★ 601.9K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $5,355,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | $150.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.38 | $5.28 |
| 52 Week High | $125.00 | $17.25 |
| Indicator | KELYB | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 32.96 |
| Support Level | $21.75 | $9.78 |
| Resistance Level | $24.77 | $11.18 |
| Average True Range (ATR) | 0.55 | 0.65 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 50.76 | 26.61 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.